Violeta Beleva Guthrie

Violeta Beleva Guthrie

Auto-generated profile, based on publicly available information

Violeta Beleva Guthrie

Abbott (United States) 1 , Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Gastroenterology
Verified
Journal Article
Open access
PDF file
CFCatherine G. Fischer
Catherine G. Fischer
VGVioleta Beleva Guthrie
Violeta Beleva Guthrie
ABAlicia M. Braxton
Alicia M. Braxton
LZLily Zheng
Lily Zheng
PWPei Wang
Pei Wang
LWLaura D. Wood
Laura D. Wood
Background & Aims Intraductal papillary mucinous neoplasms (IPMNs) are lesions that can progress to invasive pancreatic cancer and constitute an important system for studies of pancreatic tumorigenesis. We performed comprehensive genomic analyses of entire IPMNs to determine the diversity of somatic mutations in genes that promote tumorigenesis. Methods We microdissected neoplastic tissues from 6–24 regions each of 20 resected IPMNs, resulting in 227 neoplastic samples that were analyzed by capture-based targeted sequencing. Somatic mutations in genes associated with pancreatic tumorigenesis were assessed across entire IPMN lesions, and the resulting data were supported by evolutionary modeling, whole-exome sequencing, and in situ detection of mutations. Results We found a high prevalence of heterogeneity among mutations in IPMNs. Heterogeneity in mutations in KRAS and GNAS was significantly more prevalent in IPMNs with low-grade dysplasia than in IPMNs with high-grade dysplasia (P < .02). Whole-exome sequencing confirmed that IPMNs contained multiple independent clones, each with distinct mutations, as originally indicated by targeted sequencing and evolutionary modeling. We also found evidence for convergent evolution of mutations in RNF43 and TP53, which are acquired during later stages of tumorigenesis. Conclusions In an analysis of the heterogeneity of mutations throughout IPMNs, we found that early-stage IPMNs contain multiple independent clones, each with distinct mutations, indicating their polyclonal origin. These findings challenge the model in which pancreatic neoplasms arise from a single clone. Increasing our understanding of the mechanisms of IPMN polyclonality could lead to strategies to identify patients at increased risk for pancreatic cancer.

24 May 2024 in Cancer Letters
Verified
Journal Article
Open access
YBYohan Bossé
Yohan Bossé
ADAbhijit Dasgupta
Abhijit Dasgupta
MAMichael Abadier
Michael Abadier
VGVioleta Guthrie
Violeta Guthrie
FSFlorian Song
Florian Song
PJPhilippe Joubert
Philippe Joubert
Circulating tumor DNA (ctDNA) positivity at diagnosis, which is associated with worse outcomes in multiple solid tumors including stage I-III non-small cell lung cancer (NSCLC), may have utility to guide (neo)adjuvant therapy. In this retrospective study, 260 patients with clinical stage I NSCLC (180 adenocarcinoma, 80 squamous cell carcinoma) were allocated (2:1) to high- and low-risk groups based on relapse versus disease-free status ≤5 years post-surgery. We evaluated the association of preoperative ctDNA detection by a plasma-only targeted methylation-based multi-cancer early detection (MCED) test with NSCLC relapse ≤5 years post-surgery in the overall population, followed by histology-specific subgroup analyses. Across clinical stage I patients, preoperative ctDNA detection did not associate with relapse within 5 years post-surgery. Sub-analyses confined to lung adenocarcinoma suggested a histology-specific association between ctDNA detection and outcome. In this group, ctDNA positivity tended to associate with relapse within 2 years, suggesting prognostic implications of MCED test positivity may be histology- and time-dependent in stage I NSCLC. Preoperative ctDNA detection was associated with upstaging of clinical stage I to pathological stage II-III NSCLC. Our findings suggest preoperative ctDNA detection in patients with resectable clinical stage I NSCLC using MCED, a pan-cancer screening test developed for use in an asymptomatic population, has no detectable prognostic value for relapse ≤5 years post-surgery. MCED detection may be associated with early adenocarcinoma relapse and increased pathological upstaging rates in stage I NSCLC. However, given the exploratory nature of these findings, independent validation is required.

15 November 2022 in ACS Infectious Diseases
Verified
Journal Article
Open access
MSMelissa Standley
Melissa Standley
Vincent BlayVincent Blay
Vincent Blay
VGVioleta Beleva Guthrie
Violeta Beleva Guthrie
JKJay Kim
Jay Kim
ALAudrey Lyman
Audrey Lyman
MCManel Camps
Manel Camps
Multiple mutations often have non-additive (epistatic) phenotypic effects. Epistasis is of fundamental biological relevance but is not well understood mechanistically. Adaptive evolution, i.e., the evolution of new biochemical activities, is rich in epistatic interactions. To better understand the principles underlying epistasis during genetic adaptation, we studied the evolution of TEM-1 β-lactamase variants exhibiting cefotaxime resistance. We report the collection of a library of 487 observed evolutionary trajectories for TEM-1 and determine the epistasis status based on cefotaxime resistance phenotype for 206 combinations of 2-3 TEM-1 mutations involving 17 positions under adaptive selective pressure. Gain-of-function (GOF) mutations are gatekeepers for adaptation. To see if GOF phenotypes can be inferred based solely on sequence data, we calculated the enrichment of GOF mutations in the different categories of epistatic pairs. Our results suggest that this is possible because GOF mutations are particularly enriched in sign and reciprocal sign epistasis, which leave a major imprint on the sequence space accessible to evolution. We also used FoldX to explore the relationship between thermodynamic stability and epistasis. We found that mutations in observed evolutionary trajectories tend to destabilize the folded structure of the protein, albeit their cumulative effects are consistently below the protein's free energy of folding. The destabilizing effect is stronger for epistatic pairs, suggesting that modest or local alterations in folding stability can modulate catalysis. Finally, we report a significant relationship between epistasis and the degree to which two protein positions are structurally and dynamically coupled, even in the absence of ligand.

1 September 2025 in Cancer Research Communications
Verified
Journal Article
Open access
BGBrendan M. Giles
Brendan M. Giles
RCRachel Culp-Hill
Rachel Culp-Hill
RLRobert A. Law
Robert A. Law
CNCharles M. Nichols
Charles M. Nichols
MGMattie Goldberg
Mattie Goldberg
AMAbigail McElhinny
Abigail McElhinny
Ovarian cancer is the fifth leading cause of cancer-related deaths among women. Most patients are diagnosed at late stage (III/IV), resulting in a 5-year survival rate below 30%. This is driven by the presentation of vague abdominal symptoms that confound diagnosis at early stages (I/II) and a shortage of robust biomarkers. We are taking a novel approach for earlier ovarian cancer detection, leveraging lipids as biomarkers. We utilized untargeted ultrahigh pressure liquid chromatography–mass spectrometry to analyze sera from two large, independent cohorts (N = 433 and N = 399) designed to reflect the symptomatic population, including individuals with benign adnexal masses, early- and late-stage ovarian cancer, gastrointestinal disorders, and otherwise healthy women seeking care for symptoms. We identified a significantly altered lipid profile in ovarian cancer and early-stage ovarian cancer specifically across both cohorts compared with controls. We also profiled select protein biomarkers (cancer antigen 125, human epididymis protein 4, β-2 folate receptor α, and mucin 1) and, utilizing machine learning–based modeling, identified a proof-of-concept multiomic model consisting of less than 20 top-performing lipid and protein features. This model was trained on cohort 1 and tested on cohort 2, achieving AUCs of 92% (95% confidence interval, 87%–95%) for distinguishing ovarian cancer from controls and 88% (95% confidence interval, 83%–93%) for distinguishing early-stage ovarian cancer from controls. These findings demonstrate the clinical utility and robustness of lipids as proof-of-concept diagnostic biomarkers for early ovarian cancer within the clinically complex symptomatic population, particularly when applied in a multiomic approach. Significance: Patients with ovarian cancer endure delayed diagnosis and poor outcomes. We profiled lipids in two cohorts and integrated them with proteins in machine learning. This enabled early-stage detection in a complex range of controls.

29 October 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
VGVladimir G. Gainullin
Vladimir G. Gainullin
MMMael Manesse
Mael Manesse
FZFanglei Zhuang
Fanglei Zhuang
MGMelissa Gray
Melissa Gray
HHHee Jung Hwang
Hee Jung Hwang
FDFrank Diehl
Frank Diehl
Background: Multibiomarker blood tests have the potential to detect a broad range of cancer types and stages. In this study, we assessed the performance of a methylation and protein (MP) classifier using samples from a large, multicenter, prospectively collected case–control study. As part of the assay development process, we performed an exploratory analysis investigating the addition of a somatic mutation reflex approach (MP-reflex) on samples with scores below the threshold for a positive MP call but above a clear negative MP call. Methods: This study included 6,352 (1,438 cancer and 4,914 noncancer) samples representing all stages among 21 tumor organ types divided approximately equally between a training set and a test set. The sensitivity of the MP classifier was determined at a high specificity. The MP-reflex approach was investigated on MP samples at the same specificity threshold and detectable MP signals above prespecified lower thresholds. Results: Overall sensitivities for MP biomarkers were 50.9% (98.5% specificity), with sensitivities of 15.4%, 26.1%, 38%, 67.8%, 85.5%, and 37.5% for stages I, I and II combined, II, III, IV, and unknown, respectively. With breast and prostate cancers excluded, overall test sensitivities were 56.8%, with sensitivities of 17.2%, 30.7%, 48.6%, 73.5%, 86.5%, and 40% for stages I, I and II combined, II, III, IV, and unknown, respectively. Conclusions: MP biomarkers detected all solid cancers analyzed, including those without recommended screening and aggressive cancers with poor 5-year survival. Impact: These results demonstrate the potential clinical validity of multibiomarker testing for the detection of several cancer types.